Clinical trial · Observational
Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS
Retrospective Cohort Study of Overall Survival and Disease-free Survival in Breast Cancer Patients Who Underwent Controlled Ovarian Stimulation (COS)
NCT02745262CI-TRIAL-00021850unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of the study is to evaluate the overall survival and disease-free survival in breast cancer patients under 40 years old. They underwent controlled ovarian stimulation (COS) for fertility preservation versus women of the same age, type and stage of breast cancer, who have not been subjected to COS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collect retrospectively the follow-up data | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Controlled ovarian stimulation
- description
- No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
- interventionNames
- Other: Collect retrospectively the follow-up data
- label
- Non Controlled ovarian stimulation
- description
- No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
- interventionNames
- Other: Collect retrospectively the follow-up data
Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- Up to 60 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Age under 40 years ( at the time of diagnosis) * TNM stage I- II * Authorization of the fertility preservation multidisciplinary committee Exclusion Criteria: * Contraindications for pregnancy * previous history of infertility * Previous history of ovarian surgery * Prior chemotherapy * History of pelvic radiation * Diabetes Mellitus * Hypertension * renal failure * liver failure * autoimmune disease.
References
Publications (3)
- RESULTCobo A, Garcia-Velasco JA, Domingo J, Remohi J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013 May;99(6):1485-95. doi: 10.1016/j.fertnstert.2013.02.050. Epub 2013 Mar 29. PMID 23541405
- RESULTOktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 Jun 4;372(23):2268-9. doi: 10.1056/NEJMc1504241. No abstract available. PMID 26039611
- RESULTFrydman R, Grynberg M. Introduction: Female fertility preservation: innovations and questions. Fertil Steril. 2016 Jan;105(1):4-5. doi: 10.1016/j.fertnstert.2015.10.035. Epub 2015 Nov 21. PMID 26612064